HPTLC method for direct determination of gemifloxacin mesylate in human plasma.
Novel, simple and sensitive high performance thin-layer chromatography (HPTLC) with fluorescence detection has been successfully developed and validated for determination of gemifloxacin mesylate (GFX) in plasma samples without prior pretreatment. Montelukast (MK) was used as internal standard. GFX and MK in plasma samples were separated using a mobile phase consisting of a mixture of ethyl acetate:methanol:25% ammonia, (8:4.5:3, v/v/v). The emission intensity was measured using optical filter K400 after excitation at 342 nm. The Rf values for GFX and MK were 0.45±0.03 and 0.79±0.02, respectively. Under the optimum conditions, a linear relationship with good correlation coefficient (r=0.9965, n=6) was obtained in concentration range of 3-180 ng/band. The LOD and LOQ of the proposed method were 0.45 and 1.5 ng/band, respectively. The accuracy of the method was proved as the recovery % of GFX from spiked human plasma was 94.21-101.85%. The efficiency of the proposed method was confirmed by in-vivo application on human plasma in real patient samples. Moreover, the stability of GFX in plasma was carefully tested at different conditions and compared to others in aqueous solution.
['El-Koussi|W M|WM|', 'Atia|N N|NN|', 'Mahmoud|A M|AM|', 'El-Shabouri|S R|SR|']
D002855:Chromatography, Thin Layer D004355:Drug Stability D024841:Fluoroquinolones D000077735:Gemifloxacin D006801:Humans D016014:Linear Models D009287:Naphthyridines D015203:Reproducibility of Results D012680:Sensitivity and Specificity D013050:Spectrometry, Fluorescence
HPTLC Gemifloxacin mesylate Human plasma Fluorescence detection